Streetbeat News

Stock Prices

EVR

Evercore (NYSE: EVR) reported Q4 adjusted sales of $790.30 million, surpassing the analyst consensus estimate of $716.45 million by 10.31%. However, this represents a 5.54% decrease from the $836.68 million in sales reported in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 11:46 am

BSX

Boston Scientific projects net sales growth of 8.5%-9.5% year-over-year on a reported basis and 8%-9% on an organic basis for the full year 2024. The company anticipates adjusted EPS to be between $2.23 and $2.27, aligning with the consensus estimate of $2.24.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 11:43 am

MKTX

MarketAxess Holdings (NASDAQ:MKTX) reported Q4 earnings of $1.84 per share, surpassing the consensus estimate of $1.73, representing a 16.46% increase from the previous year. However, sales of $197.25M slightly missed the estimate of $197.33M, though they were up 10.87% from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 11:32 am

BSX

Boston Scientific (NYSE:BSX) exceeded analyst expectations for Q4 with an adjusted EPS of $0.55, surpassing the estimate of $0.51, and reported sales of $3.73B, beating the $3.59B estimate. These figures represent a 22.22% increase in EPS and a 14.90% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 11:32 am

CMCO

Columbus McKinnon (NASDAQ:CMCO) exceeded analyst expectations for Q3 with an adjusted EPS of $0.74, surpassing the estimate of $0.68, and reported sales of $254.10M, beating the estimate of $250.34M. These figures represent a 2.78% increase in EPS and a 10.30% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 11:31 am

CATX

EXFY

RAVE

Insiders at Expensify, Perspective Therapeutics, and Rave Restaurant Group have recently made significant stock purchases. Expensify's 10% owner bought shares at $1.76 each, following a price target increase by Piper Sandler. Perspective Therapeutics' director acquired shares at $0.58 each, with B. Riley Securities initiating coverage with a Buy rating. Rave Restaurant Group's insider purchased shares at $1.96 each after a reported increase in Q4 sales.

Portfolio Pulse from Avi Kapoor

January 31, 2024 | 11:31 am

MPLX

Raymond James analyst Justin Jenkins has reaffirmed an Outperform rating on MPLX LP (NYSE:MPLX) and increased the price target from $44 to $45.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 11:28 am

AMD

Citigroup analyst Christopher Danely has reaffirmed a Buy rating on Advanced Micro Devices (NASDAQ:AMD) and increased the price target from $136 to $192, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 11:27 am

AMD

Goldman Sachs analyst Toshiya Hari has reaffirmed a Buy rating on Advanced Micro Devices (AMD) and increased the price target from $157 to $180. This reflects a positive outlook on AMD's future performance.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 11:25 am

GM

TSLA

General Motors Co (NYSE:GM) plans to cut $1 billion in expenses at its self-driving unit Cruise in 2024 after reporting a $3.48 billion operating loss in 2023. GM CEO Mary Barra reaffirmed commitment to Cruise, considering both internal and external funding for its relaunch. Tesla CEO Elon Musk mocked investors, including T. Rowe Price, for choosing Cruise over Tesla, referencing T. Rowe Price's 2019 investment in Cruise after reducing its Tesla stake. Cruise faces safety concerns and investigations by the DOJ and SEC after an accident.

Portfolio Pulse from Anan Ashraf

January 31, 2024 | 11:19 am